| Missing Links?: 24 Citation Matrix | Graphs | Glossary HistCite Guide About |
|
EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M SCIENCE 304 (5676): 1497-1500 JUN 4 2004 and the citing papers |
Nodes: 555,
Authors: 2608,
Journals: 174,
Outer References: 17084,
Words: 1428
Collection span: 2004 - 2006
View: Overview. Sorted by year, source, volume, issue, page.
Page 1 of 6: [ 1 2 3 4 5 6 ]
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
|---|---|---|---|---|---|
| 1 | 1 | 8 | 1 2004 AMERICAN FAMILY PHYSICIAN 70 (9): 1637-+ Collins F Genomics and the family physician: Realizing the potential | 0 | 1 |
| 2 | 2 | 39 | 2 2004 ANNALES DE PATHOLOGIE 24 (5): 416-426 Penault-Llorca F; Sobourin JC The pathologist and EGFR in 2004: I like you, so don't I | 0 | 0 |
| 3 | 1 | 15 | 3 2004 ANNALS OF ONCOLOGY 15: 81-83 Giaccone G Twenty-five years of treating advanced NSCLC: what have we achieved? | 0 | 0 |
| 4 | 1 | 144 | 4 2004 BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER 1705 (1): 53-66 Cummings J; Ward TH; Ranson M; Dive C Apoptosis pathway-targeted drugs - from the bench to the clinic | 1 | 2 |
| 5 | 1 | 41 | 5 2004 BREAST CANCER RESEARCH 6 (5): 204-210 Lin NU; Winer EP New targets for therapy in breast cancer - Small molecule tyrosine kinase inhibitors | 1 | 3 |
| 6 | 1 | 25 | 6 2004 BRITISH JOURNAL OF CANCER 91: S1-S2 Camus P Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management - Introduction | 0 | 0 |
| 7 | 1 | 44 | 7 2004 BRITISH JOURNAL OF CANCER 91 (7): 1301-1307 Swinson DEB; Cox G; O'Byrne KJ Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer | 3 | 3 |
| 8 | 1 | 29 | 8 2004 CANCER 101 (7): 1632-1638 Shah L; Walter KL; Borczuk AC; Kawut SM; Sonett JR; et al. Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma | 1 | 5 |
| 9 | 1 | 86 | 9 2004 CANCER 101 (8): 1733-1744 Gridelli C; Massarelli E; Maione P; Rossi A; Herbst RS; et al. Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly | 0 | 1 |
| 10 | 1 | 12 | 10 2004 CANCER BIOLOGY & THERAPY 3 (9): 911-915 Mihich E Cancer therapeutics - Personal experiences and future perspectives | 0 | 0 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 11 | 1 | 63 | 11 2004 CANCER CELL 6 (3): 209-214 Ishizawar R; Parsons SJ c-Src and cooperating partners in human cancer | 3 | 13 |
| 12 | 1 | 63 | 12 2004 CANCER CELL 6 (4): 321-326 Abbruzzese JL; Lippman SM The convergence of cancer prevention and therapy in early-phase clinical drug development | 1 | 8 |
| 13 | 3 | 76 | 13 2004 CANCER CELL 6 (5): 433-438 Weir B; Zhao XJ; Meyerson M Somatic alterations in the human cancer genome | 2 | 3 |
| 14 | 1 | 22 | 14 2004 CANCER RESEARCH 64 (20): 7241-7244 Tracy S; Mukohara T; Hansen M; Meyerson M; Johnson BE; et al. Gefitinib induces apoptosis in the EGFR(L858R) non-small-cell lung cancer cell line H3255 | 26 | 29 |
| 15 | 1 | 45 | 15 2004 CANCER RESEARCH 64 (23): 8723-8730 Chen YL; Law PY; Loh HH Inhibition of Akt/protein kinase B signaling by naltrindole in small cell lung cancer cells | 0 | 3 |
| 16 | 1 | 20 | 16 2004 CANCER RESEARCH 64 (24): 8816-8820 Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; et al. Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia | 1 | 14 |
| 17 | 2 | 29 | 17 2004 CANCER RESEARCH 64 (24): 8919-8923 Kosaka T; Yatabe Y; Endoh H; Kuwano H; Takahashi T; et al. Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications | 48 | 51 |
| 18 | 1 | 32 | 18 2004 CANCER RESEARCH 64 (24): 9093-9100 Reyzer ML; Caldwell RL; Dugger TC; Forbes JT; Ritter CA; et al. Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics | 1 | 4 |
| 19 | 2 | 15 | 19 2004 CANCER RESEARCH 64 (24): 9101-9104 Arao T; Fukumoto H; Takeda M; Tamura T; Saijo N; et al. Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474 | 8 | 10 |
| 20 | 1 | 10 | 20 2004 CELL CYCLE 3 (7): 833-835 Druker BJ Imatinib: Paradigm or anomaly? | 4 | 5 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 21 | 2 | 83 | 21 2004 CELL CYCLE 3 (8): 1035-1042 Blagosklonny MV Analysis of FDA approved anticancer drugs reveals the future of cancer therapy | 2 | 4 |
| 22 | 1 | 32 | 22 2004 CELL CYCLE 3 (10): 1221-1224 Samuels Y; Velculescu VE Oncogenic mutations of PIK3CA in human cancers | 2 | 8 |
| 23 | 2 | 8 | 23 2004 CELL CYCLE 3 (12): 1496-1497 Settleman J Inhibition of mutant EGF receptors by Gefitinib - Targeting an Achilles' heel of lung cancer | 3 | 4 |
| 24 | 1 | 24 | 24 2004 CLINICAL CANCER RESEARCH 10 (19): 6522-6527 Messersmith WA; Laheru DA; Senzer NN; Donehower RC; Grouleff P; et al. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): Early termination due to increased toxicities | 2 | 6 |
| 25 | 1 | 36 | 25 2004 CLINICAL CANCER RESEARCH 10 (21): 7311-7317 Kim YH; Ishii G; Goto K; Nagai K; Tsuta K; et al. Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung | 2 | 3 |
| 26 | 1 | 37 | 26 2004 CLINICAL CANCER RESEARCH 10 (22): 7547-7554 Petty WJ; Dragnev KH; Memoli VA; Ma Y; Desai NB; et al. Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers | 2 | 8 |
| 27 | 1 | 48 | 27 2004 CLINICAL CANCER RESEARCH 10 (22): 7764-7774 Kalish LH; Kwong RA; Cole IE; Gallagher RM; Sutherland RL; et al. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines | 2 | 4 |
| 28 | 1 | 25 | 28 2004 CLINICAL CANCER RESEARCH 10 (24): 8195-8203 Huang SF; Liu HP; Li LH; Ku YC; Fu YN; et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan | 37 | 39 |
| 29 | 1 | 41 | 29 2004 CLINICAL CANCER RESEARCH 10 (24): 8351-8356 Thomas GV; Horvath S; Smith BL; Crosby K; Lebel LA; et al. Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer | 0 | 0 |
| 30 | 1 | 30 | 30 2004 CLINICAL CANCER RESEARCH 10 (24): 8594-8602 Schiff BA; McMurphy AB; Jasser SA; Younes MN; Doan D; et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer | 0 | 4 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 31 | 1 | 38 | 31 2004 CLINICAL CANCER RESEARCH 10 (24): 8613-8619 Onn A; Isobe T; Wu WJ; Itasaka S; Shintani T; et al. Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer | 0 | 0 |
| 32 | 1 | 109 | 32 2004 CURRENT MOLECULAR MEDICINE 4 (8): 855-868 Dharmawardana PG; Giubellino A; Bottaro DP Hereditary papillary renal carcinoma type I | 0 | 2 |
| 33 | 1 | 77 | 33 2004 CURRENT OPINION IN CELL BIOLOGY 16 (6): 670-678 Senderowicz AM Targeting cell cycle and apoptosis for the treatment of human malignancies | 0 | 3 |
| 34 | 1 | 78 | 34 2004 CURRENT OPINION IN CHEMICAL BIOLOGY 8 (4): 432-441 Mazitschek R; Giannis A Inhibitors of angiogenesis and cancer-related receptor tyrosine kinases | 1 | 4 |
| 35 | 1 | 31 | 35 2004 CURRENT OPINION IN ONCOLOGY 16 (6): 536-541 Loi S; Buyse M; Sotiriou C; Cardoso F Challenges in breast cancer clinical trial design in the postgenomic era | 0 | 0 |
| 36 | 1 | 85 | 36 2004 DRUG DEVELOPMENT RESEARCH 62 (2): 86-96 Hakonarsson H; Stefansson K Role of pharmacogenomics in drug development | 0 | 2 |
| 37 | 1 | 79 | 37 2004 DRUG DISCOVERY TODAY 9 (14): 610-618 Savage SA; Chanock SJ Using germ-line genetic variation to investigate and treat cancer | 0 | 1 |
| 38 | 1 | 56 | 38 2004 DRUG DISCOVERY TODAY 9 (18): 795-802 Desany B; Zhang ZM Bioinformatics and cancer target discovery | 0 | 1 |
| 39 | 1 | 84 | 39 2004 DRUG RESISTANCE UPDATES 7 (4-5): 245-255 Alaoui-Jamali MA; Dupre I; Qiang H Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling | 0 | 1 |
| 40 | 4 | 88 | 40 2004 DRUGS 64 (21): 2475-2492 Frampton JE; Easthope SE Gefitinib - A review of its use in the management of advanced non-small-cell lung cancer | 0 | 5 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 41 | 1 | 244 | 41 2004 ENDOCRINE-RELATED CANCER 11 (4): 659-687 Carter P; Smith L; Ryan M Identification and validation of cell surface antigens for antibody targeting in oncology | 0 | 0 |
| 42 | 1 | 135 | 42 2004 ENDOCRINE-RELATED CANCER 11 (4): 689-708 Harari PM Epidermal growth factor receptor inhibition strategies in oncology | 2 | 12 |
| 43 | 1 | 152 | 43 2004 EUROPEAN JOURNAL OF PHARMACOLOGY 500 (1-3): 267-280 Nebert DW; Vesell ES Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead | 2 | 13 |
| 44 | 1 | 99 | 44 2004 EXPERT OPINION ON INVESTIGATIONAL DRUGS 13 (12): 1569-1577 Zhang H; Yee D The therapeutic potential of agents targeting the type I insulin-like growth factor receptor | 0 | 3 |
| 45 | 1 | 92 | 45 2004 EXPERT OPINION ON PHARMACOTHERAPY 5 (7): 1621-1633 Humblet Y Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours | 1 | 2 |
| 46 | 2 | 34 | 46 2004 HUMAN MOLECULAR GENETICS 13 (24): 3029-3043 Kakiuchi S; Daigo Y; Ishikawa N; Furukawa C; Tsunoda T; et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839) | 2 | 5 |
| 47 | 1 | 27 | 47 2004 JOURNAL OF CHROMATOGRAPHY A 1053 (1-2): 279-290 Marko-Varga GA; Fehniger TE Microscale protein expression profiling during disease evolvement | 0 | 5 |
| 48 | 1 | 22 | 48 2004 JOURNAL OF CLINICAL ONCOLOGY 22 (16): 3209-3211 Dubinett SM; Elashoff D; Meyerson M Assessing prognosis in non-small-cell lung cancer: Avenues to a more complete picture? | 0 | 0 |
| 49 | 1 | 44 | 49 2004 JOURNAL OF CLINICAL ONCOLOGY 22 (16): 3238-3247 Perez-Soler R; Chachoua A; Hammond LA; Rowinsky EK; Huberman M; et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer | 42 | 57 |
| 50 | 1 | 43 | 50 2004 JOURNAL OF CLINICAL ONCOLOGY 22 (20): 4031-4034 Oliveira AM; Fletcher CDM Molecular prognostication for soft tissue sarcomas: Are we ready yet? | 0 | 3 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 51 | 1 | 19 | 51 2004 JOURNAL OF CLINICAL ONCOLOGY 22 (22): 4442-4445 Ratain MJ; Eckhardt SG Phase II studies of modern drugs directed against new targets: If you are fazed, too, then resist RECIST | 1 | 2 |
| 52 | 1 | 42 | 52 2004 JOURNAL OF CLINICAL ONCOLOGY 22 (23): 4725-4729 Shuch B; Mikhail M; Satagopan J; Lee P; Yee H; et al. Racial disparity of epidermal growth factor receptor expression in prostate cancer | 1 | 2 |
| 53 | 2 | 19 | 53 2004 JOURNAL OF THE NATIONAL CANCER INSTITUTE 96 (15): 1117-1119 Pao W; Miller VA; Venkatraman E; Kris MG Predicting sensitivity of non-small-cell lung cancer to gefitinib: Is there a role for P-akt? | 6 | 9 |
| 54 | 1 | 49 | 54 2004 JOURNAL OF THE NATIONAL CANCER INSTITUTE 96 (15): 1133-1141 Cappuzzo F; Magrini E; Ceresoli GL; Bartolini S; Rossi E; et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer | 45 | 63 |
| 55 | 1 | 12 | 55 2004 M S-MEDECINE SCIENCES 20 (8-9): 750-751 Besse B; Le Chevalier T; Soria JC Selection of patients responsive to lressa((R)) | 0 | 0 |
| 56 | 1 | 74 | 56 2004 MOLECULAR CANCER THERAPEUTICS 3 (10): 1335-1342 Britten CD Targeting ErbB receptor signaling: A pan-ErbB approach to cancer | 5 | 5 |
| 57 | 1 | 7 | 57 2004 NATURE 430 (6995): 30-30 Stratton MR; Futreal PA Cancer - Understanding the target | 2 | 3 |
| 58 | 1 | 8 | 58 2004 NATURE 431 (7008): 525-526 Stephens P; Hunter C; Bignell G; Edkins S; Davies H; et al. Intragenic ERBB2 kinase mutations in tumours | 45 | 53 |
| 59 | 3 | 31 | 59 2004 NATURE 432 (7015): 294-297 Sawyers C Targeted cancer therapy | 8 | 18 |
| 60 | 2 | 98 | 60 2004 NATURE 432 (7015): 298-306 Massague J G1 cell-cycle control and cancer | 1 | 34 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 61 | 1 | 11 | 61 2004 NATURE BIOTECHNOLOGY 22 (10): 1215-1217 Hood L; Perlmutter RM The impact of systems approaches on biological problems in drug discovery | 1 | 10 |
| 62 | 1 | 2 | 62 2004 NATURE MEDICINE 10 (8): 764-764 Katsnelson A Experts call for smarter approach to targeted therapies | 0 | 1 |
| 63 | 1 | 118 | 63 2004 NATURE MEDICINE 10 (8): 789-799 Vogelstein B; Kinzler KW Cancer genes and the pathways they control | 13 | 118 |
| 64 | 2 | 26 | 64 2004 NATURE MEDICINE 10 (12): 1289-1291 Evans BJ; Flockhart DA; Meslin EM Creating incentives for genomic research to improve targeting of therapies | 0 | 0 |
| 65 | 1 | 85 | 65 2004 NATURE REVIEWS CANCER 4 (9): 718-727 Dibb NJ; Dilworth SM; Mol CD Opinion - Switching on kinases: oncogenic activation of BRAF and the PDGFR family | 6 | 16 |
| 66 | 1 | 37 | 66 2004 NATURE REVIEWS CANCER 4 (10): 820-828 von Eschenbach AC A vision for the National Cancer Program in the United States | 2 | 9 |
| 67 | 3 | 88 | 67 2004 NATURE REVIEWS CANCER 4 (12): 956-965 Herbst RS; Fukuoka M; Baselga J Timeline - Gefitinib - a novel targeted approach to treating cancer | 10 | 18 |
| 68 | 1 | 71 | 68 2004 NATURE REVIEWS DRUG DISCOVERY 3 (9): 739-748 Weinshilboum R; Wang LW Pharmacogenomics: Bench to bedside | 0 | 15 |
| 69 | 1 | 84 | 69 2004 NATURE REVIEWS DRUG DISCOVERY 3 (9): 749-761 Koch WH Technology platforms for pharmacogenomic diagnostic assays | 1 | 8 |
| 70 | 1 | 10 | 70 2004 NATURE REVIEWS DRUG DISCOVERY 3 (9): 763-769 Lesko LJ; Woodcock J Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective | 3 | 18 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 71 | 3 | 92 | 71 2004 NATURE REVIEWS DRUG DISCOVERY 3 (12): 1001-1010 Daub H; Specht K; Ullrich A Strategies to overcome resistance to targeted protein kinase inhibitors | 7 | 24 |
| 72 | 1 | 118 | 72 2004 NATURE REVIEWS DRUG DISCOVERY 3 (12): 1011-1022 Yingling JM; Blanchard KL; Sawyer JS Development of TGF-beta signalling inhibitors for cancer therapy | 0 | 13 |
| 73 | 1 | 65 | 73 2004 NATURE REVIEWS GENETICS 5 (9): 645-656 Roses AD Pharmacogenetics and drug development: The path to safer and more effective drugs | 1 | 21 |
| 74 | 1 | 101 | 74 2004 NATURE REVIEWS NEUROSCIENCE 5 (10): 782-792 Mischel PS; Cloughesy TF; Nelson SF DNA-microarray analysis of brain cancer: Molecular classification for therapy | 1 | 11 |
| 75 | 1 | 14 | 75 2004 NEW ENGLAND JOURNAL OF MEDICINE 351 (5): 501-505 Roberts TG; Chabner BA Sounding board: Beyond fast track for drug approvals | 2 | 3 |
| 76 | 1 | 2 | 76 2004 NEW ENGLAND JOURNAL OF MEDICINE 351 (12): 1260-1260 Rich JN; Rasheed BKA; Yan H EGFR mutations and sensitivity to gefitinib | 4 | 4 |
| 77 | 1 | 5 | 77 2004 NEW ENGLAND JOURNAL OF MEDICINE 351 (27): 2883-2883 Barber TD; Vogelstein B; Kinzler KW; Velculescu VE Somatic mutations of EGFR in colorectal cancers and glioblastomas | 20 | 25 |
| 78 | 1 | 76 | 78 2004 NUCLEIC ACIDS RESEARCH 32 (19): Art. No. e148 Pincas H; Pingle MR; Huang JM; Lao KQ; Paty PB; et al. High sensitivity EndoV mutation scanning through real-time ligase proofreading | 0 | 0 |
| 79 | 2 | 62 | 79 2004 ONCOGENE 23 (51): 8392-8400 Willingham AT; Deveraux QL; Hampton GM; Aza-Blanc P RNAi and HTS: exploring cancer by systematic loss-of-function | 1 | 5 |
| 80 | 1 | 15 | 80 2004 ONCOLOGIST 9 (4): 357-360 Druker BJ Molecularly targeted Therapy: Have the floodgates opened? | 1 | 3 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 81 | 1 | 18 | 81 2004 PHARMACOGENOMICS 5 (8): 1167-1173 Campbell DA; Carmichael J; Chopra R Molecular pathology in oncology - the AstraZeneca perspective | 1 | 1 |
| 82 | 1 | 29 | 82 2004 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 101 (36): 13306-13311 Pao W; Miller V; Zakowski M; Doherty J; Politi K; et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib | 184 | 209 |
| 83 | 1 | 74 | 83 2004 RADIOTHERAPY AND ONCOLOGY 72 (3): 257-266 Baumann M; Krause M Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results | 2 | 16 |
| 84 | 3 | 9 | 84 2004 RESPIROLOGY 9 (4): 426-427 Fong KM; Bowman R A molecular chink in the lung cancer armour | 0 | 0 |
| 85 | 1 | 3 | 85 2004 SCHIZOPHRENIA RESEARCH 72 (1): 75-77 Scolnick E Program to improve cognitive functioning in patients with schizophrenia: reflections | 0 | 2 |
| 86 | 1 | 6 | 86 2004 SCIENCE 304 (5676): 1458-+ Minna JD; Gazdar AF; Sprang SR; Herz J Cancer - A bull's eye for targeted lung cancer therapy | 14 | 17 |
| 87 | 0 | 26 | 87 2004 SCIENCE 304 (5676): 1497-1500 Paez JG; Janne PA; Lee JC; Tracy S; Greulich H; et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy | 554 | 555 |
| 88 | 1 | 19 | 88 2004 SCIENCE 305 (5687): 1163-1167 Sordella R; Bell DW; Haber DA; Settleman J Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways | 107 | 132 |
| 89 | 1 | 8 | 89 2004 SCIENTIST 18 (15): 26-27 May M Pharmacogenomics lurches forward - Small battles push toward making personalized medicine a reality | 0 | 0 |
| 90 | 1 | 66 | 90 2004 SEMINARS IN ONCOLOGY 31 (5): 6-13 Yarden Y; Baselga J; Miles D Molecular approach to breast cancer treatment | 0 | 4 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 91 | 1 | 28 | 91 2004 SEMINARS IN ONCOLOGY 31 (6): 27-31 Govindan R; Garfield DH Treatment approaches in patients with advanced non-small cell lung cancer and poor performance status | 0 | 0 |
| 92 | 3 | 34 | 92 2004 TRENDS IN MOLECULAR MEDICINE 10 (10): 481-486 Gazdar AF; Shigematsu H; Herz J; Minna JD Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? | 16 | 20 |
| 93 | 1 | 69 | 93 2004 TRENDS IN PHARMACOLOGICAL SCIENCES 25 (9): 457-464 Petros WP; Evans WE Pharmacogenomics in cancer therapy: is host genome variability important? | 0 | 2 |
| 94 | 1 | 27 | 94 2004 XENOBIOTICA 34 (10): 901-915 McKillop D; Partridge EA; Hutchison M; Rhead SA; Parry AC; et al. Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog | 1 | 3 |
| 95 | 1 | 55 | 95 2005 ACTA HISTOCHEMICA ET CYTOCHEMICA 38 (3): 209-216 Tani Y; Hatanaka Y; Hashizume K Development of precise pharmocodiagnostic (PharmDx) tests for molecular targeted therapies | 0 | 0 |
| 96 | 1 | 15 | 96 2005 ACTA ONCOLOGICA 44 (7): 717-722 Hotta K; Ueoka H; Kiura K; Tabata M; Ogino A; et al. Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience | 0 | 0 |
| 97 | 2 | 19 | 97 2005 ADVANCES IN ANATOMIC PATHOLOGY 12 (2): 47-52 Chang KL; Lau SK EGFR mutations in non-small cell lung carcinomas may predict response to gefitinib - Extension of an emerging paradigm | 0 | 0 |
| 98 | 1 | 190 | 98 2005 ALIMENTARY PHARMACOLOGY & THERAPEUTICS 21 (4): 321-339 Jalving M; Koornstra JJ; De Jong S; De Vries EGE; Kleibeuker JH Review article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer | 0 | 0 |
| 99 | 2 | 18 | 99 2005 AMERICAN JOURNAL OF CLINICAL PATHOLOGY 124 (1): 20-23 Le LH; Chetty R; Moore MJ Epidermal growth factor receptor expression in anal canal carcinoma | 0 | 0 |
| 100 | 3 | 125 | 100 2005 AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY 13 (12): 1027-1040 Gershenfeld HK; Philibert RA; Boehm GW Looking forward in geriatric anxiety and depression - Implications of basic science for the future | 0 | 1 |
Page 1 of 6: [ 1 2 3 4 5 6 ]
Generated by: HistCite 2005.08.29